Skip to main content
SpringerLink
Log in

Treatment of Melanoma and Nonmelanoma Skin Cancer

  • Chapter
Sunlight, Vitamin D and Skin Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 624))

Abstract

The incidence of skin cancer is increasing in Caucasian populations worldwide. Treatment approaches for Nonmelanoma skin cancer (NMSC) are predominandy curative and surgery can be regarded as standard of care. Nevertheless, novel and less invasive topical therapy modalities like photodynamic therapy or local immune modifiers are in progress.

In contrast to NMSC, the mortality of melanoma has not changed considerably over the last years and decades. Melanoma survival mainly depends on primary tumor thickness underlining the importance of primary and secondary prevention by avoidance or early detection of the disease. The chance to cure melanoma patients is steadily decreasing with tumor stage. As the prognosis in distant metastatic disease is still poor, except for single situations therapy approaches are palliative and accompanied by an optimal supportive care of the patients concerned. Albeit removal of localized metastases is currently the most effective approach in metastatic melanoma, chemo- and chemoimmunotherapy has to be regarded as standard treatment in most of the cases.

Novel and promising therapeutic options accrue from growing insights in tumor biology and immunology. Not only in melanoma, development and application of targeted therapies currendy attract the most attention in the treatment of advanced tumors. First clinical experiences with those antiproliferative, antiangiogenic and proapoptotic agents reveal only moderate antitumoral activity in melanoma, so that future efforts aim at defining more effective combination strategies using chemo-, targeted and vaccination therapy approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117–127.

    Article  PubMed  Google Scholar 

  2. Balch CM, Soong SJ, Gerschenwald JE et al. Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–3634.

    PubMed  CAS  Google Scholar 

  3. Ringborg U, Andersson R, Eldh J et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996;77:1809–1814.

    Article  PubMed  CAS  Google Scholar 

  4. Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:1159–1162.

    Article  PubMed  CAS  Google Scholar 

  5. Thomas JM, Newton-Bishop J, A’Hern R et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757–766.

    Article  PubMed  CAS  Google Scholar 

  6. Hauschild A, Rosien F, Lischner S. Surgical standards in the primary care of melanoma patients. Onkologie 2003;26:218–222.

    Article  PubMed  CAS  Google Scholar 

  7. Cascinelli N, Morabito A, Santinami M et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. Lancet 1998;351:793–796.

    Article  PubMed  CAS  Google Scholar 

  8. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–982.

    PubMed  CAS  Google Scholar 

  9. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.

    PubMed  CAS  Google Scholar 

  10. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307–1317.

    Article  PubMed  CAS  Google Scholar 

  11. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.

    PubMed  CAS  Google Scholar 

  12. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004;16:155–160.

    Article  PubMed  Google Scholar 

  13. Reinhardt MJ, Joe AY, Jaeger U et al. Diagnostic performance of whole body dual modality 18F-FDG-PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178–1187.

    Article  PubMed  Google Scholar 

  14. Stas M, Stroobants S, Dupont P et al 18-FDG-PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002;12:479–490.

    Article  PubMed  CAS  Google Scholar 

  15. Leo F, Cagini L, Rocmans P et al. Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 2000;83:569–572.

    Article  PubMed  CAS  Google Scholar 

  16. Tagawa ST, Cheung E, Banta W et al. Survival Analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer 2006;106:1353–1357.

    Article  PubMed  Google Scholar 

  17. Eggermont AMM, Suciu S, MacKie R et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:1189–1196.

    Article  PubMed  CAS  Google Scholar 

  18. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:1905–1910.

    Article  PubMed  CAS  Google Scholar 

  19. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:1425–1429.

    PubMed  CAS  Google Scholar 

  20. Garbe C, Hauschild A, Linse R et al. Adjuvant treatment of patients with cutaneous melanoma and regional node metastasis with low dose interferon-or interferon-plus DTIC versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG trial. 5th International Conference on the Adjuvant Therapy of Malignant Melanoma, Abstract booklet, 2004; No 1-21, p. 14.

    Google Scholar 

  21. Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866–869.

    Article  PubMed  CAS  Google Scholar 

  22. Hancock BW, Wheatley K, Harris S et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53–61.

    Article  PubMed  CAS  Google Scholar 

  23. Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444–2458.

    PubMed  CAS  Google Scholar 

  24. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.

    PubMed  CAS  Google Scholar 

  25. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.

    PubMed  CAS  Google Scholar 

  26. Creagan ET, Dalton RJ, Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776–2783.

    PubMed  CAS  Google Scholar 

  27. Verma S, Quirt I, McCready D et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431–1442.

    Article  PubMed  CAS  Google Scholar 

  28. Mohr P, Weichenthal M, Hauschild A. Adjuvant therapy in melanoma. Onkologie 2003;26:227–233.

    Article  PubMed  CAS  Google Scholar 

  29. Tilgen W. Malignant melanoma: current therapeutic concepts. Onkologie 1995;18:534–547.

    Article  Google Scholar 

  30. Sondak VK, Sosman J, Unger JM et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 [abstract 7501]. Proc Am Soc Clin Oncol 2004;14S:22.

    Google Scholar 

  31. Koops HS, Vaglini M, Suciu S et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter reandomized phase HI trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15 and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998;16:2906–2912.

    PubMed  CAS  Google Scholar 

  32. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045–2052.

    Article  PubMed  CAS  Google Scholar 

  33. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455–464.

    Article  PubMed  CAS  Google Scholar 

  34. Rass K, Tadler D, Tilgen W. Therapy of malignant melanoma. First-, second-and pathogenesis-oriented third-line therapies. Hautarzt 2006;57:773–784.

    Article  PubMed  CAS  Google Scholar 

  35. Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007 (1):CD005413.

    Google Scholar 

  36. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastastic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825–1836.

    Article  PubMed  CAS  Google Scholar 

  37. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738–4745.

    Article  PubMed  CAS  Google Scholar 

  38. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563–570.

    Article  PubMed  CAS  Google Scholar 

  39. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastastatic melanoma. J Clin Oncol 2000;18:158–66.

    PubMed  CAS  Google Scholar 

  40. Danson S, Lorigan P. Improving outcomes in advanced malignant melanoma—Update on systemic therapy. Drugs 2005;65:733–743.

    Article  PubMed  CAS  Google Scholar 

  41. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase II study. J Clin Oncol 2004;22:1118–25.

    Article  PubMed  CAS  Google Scholar 

  42. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745–2751.

    PubMed  CAS  Google Scholar 

  43. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75–81.

    Article  PubMed  CAS  Google Scholar 

  44. Legha SS, Ring S, Bedikian A et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827–835.

    PubMed  CAS  Google Scholar 

  45. Bajetta E, Del Vecchio M, Nova P et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006;17:571–577.

    Article  PubMed  CAS  Google Scholar 

  46. Kaufinann R, Spicth K, Leiter U et al. Temozolomide in combination with Interferon-alfa versus Temozolomidc alone in patients with advanced metastatic melanoma: A randomized, Phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001–9007.

    Article  CAS  Google Scholar 

  47. Reinhold U, Hartl C, Hering R et al. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma. Lancet 1997;349:540–541.

    Article  PubMed  CAS  Google Scholar 

  48. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687–701.

    PubMed  CAS  Google Scholar 

  49. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51–58.

    Article  PubMed  CAS  Google Scholar 

  50. Ugurel S, Schadendorf D, Pföhler C et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006;12:5454–5463.

    Article  PubMed  CAS  Google Scholar 

  51. Quinn JA, Desjardins A, Weingart J et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178–87.

    Article  PubMed  CAS  Google Scholar 

  52. Ranson M, Middleton MR, Bridgewater J et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006;12:1577–84.

    Article  PubMed  CAS  Google Scholar 

  53. Ranson M, Hersey P, Thompson D et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007;25:2540–2545.

    Article  PubMed  CAS  Google Scholar 

  54. Tentori L, Leonetti C, Scarsella M et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 2005;26:415–22.

    PubMed  CAS  Google Scholar 

  55. Barranco S, Romsdahl M, Humphrey R. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1971;31:830.

    PubMed  CAS  Google Scholar 

  56. Isokangas OP, Muhonen T, Kajanti M et al. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996;38:139–144.

    Article  PubMed  CAS  Google Scholar 

  57. Buchsbaum JC, Shu JH, Lee SY et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma. Cancer 2002;94:2265–2272.

    Article  PubMed  Google Scholar 

  58. Mathieu D, Kondziolka D, Cooper PB et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007;60:471–481.

    PubMed  Google Scholar 

  59. Kirova YM, Chen J, Rabarijaona LI et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999;9:611–613.

    Article  PubMed  CAS  Google Scholar 

  60. Ballo MT, Strom EA, Zagars GK et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002;52:964–972.

    PubMed  Google Scholar 

  61. Belardelli F, Ferrantini M, Parmiani G et al. International Meeting on Cancer Vaccines: How can we enhance efficacy of therapeutic vaccines? Cancer Res 2004;64:6827–6830.

    Article  PubMed  CAS  Google Scholar 

  62. Schuler-Thurner B, Schuler G. Vaccination therapy of melanoma. J Dtsch Dermatol Ges 2005;3:630–645.

    Article  PubMed  Google Scholar 

  63. Sosman JA, Weeraratna AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol 2004;22:387–389.

    Article  PubMed  CAS  Google Scholar 

  64. Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058–2066.

    Article  PubMed  CAS  Google Scholar 

  65. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101(Suppl. 2):14639–14645.

    Article  PubMed  CAS  Google Scholar 

  66. Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol 2007;19:116–120.

    Article  PubMed  Google Scholar 

  67. Phan GQ, Yang J, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372–8377.

    Article  PubMed  CAS  Google Scholar 

  68. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with Anti-Cytotoxic T-Lymphocyte Antigen-4. J Clin Oncol 2005;23:6043–6053.

    Article  PubMed  CAS  Google Scholar 

  69. Schneeder A, Wagner C, Zemann A et al. CpG motifs are efficient adjuvants for DNA vaccines. J Invest Dermatol 2004;123:371–379.

    Article  Google Scholar 

  70. Pashenkov M, Goëss G, Wagner C et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24:5716–24.

    Article  PubMed  CAS  Google Scholar 

  71. Becker JC, Kirkwood JM, Agarwala SS et al. Molecular targeted therapy for melanoma. Current reality and future options. Cancer 2006;107:2317–2327.

    Article  PubMed  CAS  Google Scholar 

  72. Sosman JA, Puzaniv I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006; 12(Suppl. 7):2376–2383.

    Article  Google Scholar 

  73. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.

    Article  PubMed  CAS  Google Scholar 

  74. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res 2004;6:7099–7109.

    Article  Google Scholar 

  75. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients. J Clin Oncol 2005;23:965–72.

    Article  PubMed  CAS  Google Scholar 

  76. Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045–8.

    Article  PubMed  CAS  Google Scholar 

  77. Thallinger C, Poeppl W, Pratscher B et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007;79:207–13.

    Article  PubMed  CAS  Google Scholar 

  78. Wyman K, Atkins MB, Prieto V et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma. Cancer 2006;1006:2005–2011.

    Article  CAS  Google Scholar 

  79. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6.

    Article  PubMed  CAS  Google Scholar 

  80. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;21:3351–3356.

    Article  PubMed  CAS  Google Scholar 

  81. Danson S, Lorigan P, Arance A et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551–2557.

    Article  PubMed  CAS  Google Scholar 

  82. Krown SE, Niedzwiecki D, Hwu WJ et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006;107:1883–1890.

    Article  PubMed  CAS  Google Scholar 

  83. Hurwitz H, Fehrenbacher Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  84. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884–96.

    Article  PubMed  CAS  Google Scholar 

  85. Peterson AC, Swiger S, Stadler WM et al. Phase II study of thr Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004;10:4048–4054.

    Article  PubMed  CAS  Google Scholar 

  86. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opinion Investig Drugs 2003;4:722–731.

    CAS  Google Scholar 

  87. Hersey P, Sosman J, O’Day S et al. A phase II, randomized, open label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin +/-dacarbazine in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2005: Abstract 7570.

    Google Scholar 

  88. Dormond O, Foletti A, Paroz C et al. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  89. Lejeune FL, Monnier Y, Rüegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006;16:263–265.

    Article  PubMed  CAS  Google Scholar 

  90. Helmbach H, Kern MA, Rossmann E et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002;118:923–932.

    Article  PubMed  CAS  Google Scholar 

  91. Jansen B, Schlagbauer-Wadl H, Brown BD et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998;4:232–234.

    Article  PubMed  CAS  Google Scholar 

  92. Hu Y, Cherton-Horvat G, Dragowska V et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826–2836.

    PubMed  CAS  Google Scholar 

  93. Amiri KI, Horton LW, LaFleur BJ et al. Augmenting chemosensitivity of malignant melanoma tumours via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 2004;64:4912–4918.

    Article  PubMed  CAS  Google Scholar 

  94. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241–246.

    Article  PubMed  CAS  Google Scholar 

  95. Katalinic A, Kunze U, Schafer T. Epidemiology of cutaneous melanoma and nonmelanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003;149:1200–1206.

    Article  PubMed  CAS  Google Scholar 

  96. Boukamp P. Nonmelanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657–1667.

    Article  PubMed  CAS  Google Scholar 

  97. Rass K. UV damage and DNA repair in basal cell and squamous cell carcinomas. In: Reichrath J, ed. Molecular Mechanisms of Basal Cell and Squamous Cell Carcinomas. Georgetown: Landes Bioscience 2006:18–30.

    Chapter  Google Scholar 

  98. Ceilly RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol 2006;45:489–498.

    Article  Google Scholar 

  99. Rodriguez-Vigil T, Vazquez-Lopez F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol 2007;56:91–95.

    Article  PubMed  Google Scholar 

  100. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135:1177–1183.

    Article  PubMed  CAS  Google Scholar 

  101. Thissen MR, Nieman FH, Ideler AH et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000;26:759–764.

    Article  PubMed  CAS  Google Scholar 

  102. Panizzon RG. Dermatologic radiotherapy. Hautarzt 58:701–712.

    Google Scholar 

  103. Silverman MK, Kopf AW, Gladstein AH et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol 1992;18:549–554.

    PubMed  CAS  Google Scholar 

  104. Noodt BB, Berk K, Stokke T et al. Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Br J Cancer 1996;74:22–29.

    PubMed  CAS  Google Scholar 

  105. Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007;56:125–143.

    Article  PubMed  Google Scholar 

  106. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17–23.

    Article  PubMed  CAS  Google Scholar 

  107. Berman B, Sullivan T, De Araujo T et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149(Suppl. 66):59–61.

    Article  PubMed  CAS  Google Scholar 

  108. Stockfleth E, Trefzer U, Garcia-Bartels C et al. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 2003; 149(Suppl. 66):53–56.

    Article  PubMed  CAS  Google Scholar 

  109. Locke J, Karimpour S, Young G et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001;51:748–755.

    PubMed  CAS  Google Scholar 

  110. McCord MW, Mendenhall WM, Parsons JT et al. Skin cancer of the head and neck with clinical perineural invasion. Int J Radiat Oncol Biol Phys 2000;47:89–93.

    PubMed  CAS  Google Scholar 

  111. Schmook T, Stockfleth E. Current treatment patterns in nonmelanoma skin cancer across Europe. J Dermatolog Treat 2003; 14(Suppl. 3):3–10.

    Article  PubMed  Google Scholar 

  112. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14:99–106.

    Article  PubMed  CAS  Google Scholar 

  113. Szeimies RM, Gerritsen MJ, Gupta G et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547–555.

    Article  PubMed  Google Scholar 

  114. Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007;6:144–147.

    PubMed  Google Scholar 

  115. Wolf JE, Taylor JR, Tschen E et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;41:371–372.

    Google Scholar 

  116. Mendenhall NP, Million RR, Cassisi NJ. Parotid area lymph node metastases from carcinoma of the skin. Int J Radiat Oncol Biol Phys 1985;11:707–714.

    PubMed  CAS  Google Scholar 

  117. Guthrie TH Jr, Porubsky ES et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342–346.

    PubMed  Google Scholar 

  118. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991;67:2020–2032.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Saarland University Hospital Dermatology Clinic, Homburg/Saar, Germany

    Knuth Rass

  2. Clinic for Dermatology, Venerology and Allergology, The Saarland University Hospital, Homburg/Saar, Germany

    Wolfgang Tilgen

Authors
  1. Knuth Rass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Tilgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Knuth Rass .

Editor information

Editors and Affiliations

  1. Clinic for Dermatology, Venerology and Allergology, The Saarland University Hospital, Homburg/Saar, Germany

    Jörg Reichrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Rass, K., Tilgen, W. (2008). Treatment of Melanoma and Nonmelanoma Skin Cancer. In: Reichrath, J. (eds) Sunlight, Vitamin D and Skin Cancer. Advances in Experimental Medicine and Biology, vol 624. Springer, New York, NY. https://doi.org/10.1007/978-0-387-77574-6_23

Download citation

Publish with us

Policies and ethics

Search

Navigation